BR112019024230A2 - combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama - Google Patents

combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama Download PDF

Info

Publication number
BR112019024230A2
BR112019024230A2 BR112019024230A BR112019024230A BR112019024230A2 BR 112019024230 A2 BR112019024230 A2 BR 112019024230A2 BR 112019024230 A BR112019024230 A BR 112019024230A BR 112019024230 A BR112019024230 A BR 112019024230A BR 112019024230 A2 BR112019024230 A2 BR 112019024230A2
Authority
BR
Brazil
Prior art keywords
erbb
combination
breast cancer
bispecific antibody
endocrine therapy
Prior art date
Application number
BR112019024230A
Other languages
English (en)
Inventor
Andre Baptiste Maussang-Detaille David
Anna Wilhelmina Geuijen Cecilia
Original Assignee
Merus N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus N.V. filed Critical Merus N.V.
Publication of BR112019024230A2 publication Critical patent/BR112019024230A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

a invenção se refere a métodos de tratamento de um sujeito que tem câncer de mama ou está em risco de ter o referido câncer, compreendendo administrar ao sujeito em necessidade do mesmo uma combinação de uma quantidade terapeuticamente eficaz de um anticorpo biespecífico erbb-2 / erbb-3 e um quantidade terapeuticamente eficaz de um medicamento para terapia endócrina, em que o anticorpo biespecífico possui um local de ligação ao antígeno que pode se ligar a uma parte extracelular do erbb-2 e um local de ligação ao antígeno que pode se ligar a uma parte extracelular do erbb-3; e meios para o referido método.
BR112019024230A 2017-05-17 2018-05-17 combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama BR112019024230A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762507675P 2017-05-17 2017-05-17
PCT/NL2018/050329 WO2018212656A1 (en) 2017-05-17 2018-05-17 Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer

Publications (1)

Publication Number Publication Date
BR112019024230A2 true BR112019024230A2 (pt) 2020-06-09

Family

ID=62716109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024230A BR112019024230A2 (pt) 2017-05-17 2018-05-17 combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama

Country Status (15)

Country Link
US (1) US20210054096A1 (pt)
EP (1) EP3625264B9 (pt)
JP (2) JP7296891B2 (pt)
KR (1) KR20200018785A (pt)
CN (1) CN111148764A (pt)
AU (1) AU2018271157C1 (pt)
BR (1) BR112019024230A2 (pt)
CA (1) CA3063849A1 (pt)
EA (1) EA201992522A1 (pt)
ES (1) ES2951864T3 (pt)
IL (1) IL270716B2 (pt)
MX (1) MX2019013804A (pt)
PH (1) PH12019502574A1 (pt)
WO (1) WO2018212656A1 (pt)
ZA (1) ZA201907754B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3365373T3 (da) 2015-10-23 2021-04-06 Merus Nv Bindingsmolekyler, der hæmmer cancervækst
IL269656B1 (en) 2017-03-31 2024-02-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
PL2147594T3 (pl) 2008-06-27 2014-04-30 Merus Nv Wytwarzające przeciwciała ssaki inne niż człowiek
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
CA2828099A1 (en) * 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
MX2013010379A (es) * 2011-03-11 2014-03-27 Merrimack Pharmaceuticals Inc Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
LT2838918T (lt) 2012-04-20 2019-09-10 Merus N.V. Būdai ir priemonės heterodimerinių ig-tipo molekulių gamybai
WO2015077891A1 (en) * 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
SG11201607104RA (en) * 2014-02-28 2016-09-29 Merus Nv Antibody that binds erbb-2 and erbb-3

Also Published As

Publication number Publication date
KR20200018785A (ko) 2020-02-20
JP2020520377A (ja) 2020-07-09
ZA201907754B (en) 2023-11-29
CA3063849A1 (en) 2018-11-22
EP3625264B9 (en) 2023-10-25
WO2018212656A1 (en) 2018-11-22
IL270716B (en) 2022-10-01
EP3625264B1 (en) 2023-06-28
AU2018271157C1 (en) 2021-11-18
MX2019013804A (es) 2020-02-24
AU2018271157B2 (en) 2021-06-17
JP2023085422A (ja) 2023-06-20
AU2018271157A1 (en) 2019-12-05
EA201992522A1 (ru) 2020-04-22
PH12019502574A1 (en) 2020-12-07
IL270716B2 (en) 2023-02-01
EP3625264A1 (en) 2020-03-25
ES2951864T9 (es) 2023-11-29
ES2951864T3 (es) 2023-10-25
CN111148764A (zh) 2020-05-12
IL270716A (en) 2020-01-30
US20210054096A1 (en) 2021-02-25
JP7296891B2 (ja) 2023-06-23

Similar Documents

Publication Publication Date Title
BR112016026559A8 (pt) uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
CO2018003542A2 (es) Anticuerpo anti-garp
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
BR112018003984A2 (pt) anticorpos
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
BR112016013896A2 (pt) métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
BR112018069976A2 (pt) anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo.
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
UY35136A (es) Métodos para tratar el cáncer de ovario con antagonistas de dll4.
CO2019007686A2 (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo
BR112016023025A2 (pt) direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
BR112019024230A2 (pt) combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.